Prognostic significance of serum annexin A7 in severe traumatic brain injury: A prospective longitudinal cohort study

Abstract

BackgroundAnnexin A7 (ANXA7) may have the potential to exacerbate brain injury. Our purpose was to investigate the role of serum ANXA7 as a biomarker of severity and prognosis after severe traumatic brain injury (sTBI). MethodsIn this prospective cohort study, we consecutively enrolled 102 sTBI patients and 102 controls and measured their serum ANXA7 concentrations. Post-trauma 180-day poor prognosis was considered as extended Glasgow outcome scale score 1–4. ResultsSignificantly increased serum ANXA7 concentrations of sTBI patients, as compared to controls (median, 74.1 vs 8.0 ng/ml; P < 0.001), had independent correlation with Rotterdam computed tomography score (t = 3.251, P = 0.002) and Glasgow coma scale score (t = -2.253, P = 0.027), as well as serum ANXA7 concentrations > 74.1 ng/ml were independently predictive of 180-day overall survival (hazard ratio, 3.356; 95 % confidence interval (CI), 1.233–9.138; P = 0.018), and poor prognosis (OR: 3.558; 95 % CI, 1.264–10.015; P = 0.016). Serum ANXA7 concentrations were of significant efficiency for discriminating risks of mortality (area under receiver operating curve (AUC), 0.808; 95 % CI; 0.718–0.879) and poor prognosis (AUC, 0.772; 95 % CI; 0.678–0.849). Moreover, its AUC was in range of Glasgow coma scale score and Rotterdam computed tomography score (all P > 0.05) ConclusionsIncreased serum ANXA7 concentrations, in close relation to severity, were independently associated with prognosis, indicating that serum ANXA7 may represent a clinically valuable biomarker of sTBI.